Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hagin

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
The New England Journal of Medicine|May 31, 2024
Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema AttacksMarc A Riedl, Henriette Farkas, Emel Aygören-Pürsün, et al.
The Journal of Allergy and Clinical Immunology|June 12, 2017
Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutationsJennifer W Leiding, Satoshi Okada, David Hagin, et al.
Journal of Clinical Immunology|November 26, 2015
The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1Mark Depner, Sebastian Fuchs, Jan Raabe, et al.
The Lancet. Haematology|March 22, 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trialMarcus Maurer, Marcin Stobiecki, Anna Valerieva, et al.
The World Allergy Organization Journal|June 19, 2026
Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trialsEmel Aygören-Pürsün, Danny M Cohn, Nancy Agmon-Levin, et al.
Medrxiv : the Preprint Server for Health Sciences|September 15, 2025
Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohortsAdrian Gervais, Francesca Trespidi, Alessandro Ferrari, et al.
Journal of Human Immunity|March 16, 2026
Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohortsAdrian Gervais, Francesca Trespidi, Alessandro Ferrari, et al.
The Journal of Allergy and Clinical Immunology|November 7, 2023
JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective studyMarco Fischer, Peter Olbrich, Jérôme Hadjadj, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2026
ASSESSMENT OF TREC-BASED NBS SCID REPORTING PRACTICES FOR HARMONIZATION OF RESULTS AND INTERPRETATION: A GLOBAL SURVEYJahnavi Aluri, Amy Gaviglio, Isaac Kistler, et al.
Research Square|January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodiesJeremy Manry, Paul Bastard, Adrian Gervais, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
The New England Journal of Medicine|May 31, 2024
Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema AttacksMarc A Riedl, Henriette Farkas, Emel Aygören-Pürsün, et al.
The Journal of Allergy and Clinical Immunology|June 12, 2017
Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutationsJennifer W Leiding, Satoshi Okada, David Hagin, et al.
Journal of Clinical Immunology|November 26, 2015
The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1Mark Depner, Sebastian Fuchs, Jan Raabe, et al.
The Lancet. Haematology|March 22, 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trialMarcus Maurer, Marcin Stobiecki, Anna Valerieva, et al.
The World Allergy Organization Journal|June 19, 2026
Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trialsEmel Aygören-Pürsün, Danny M Cohn, Nancy Agmon-Levin, et al.
Medrxiv : the Preprint Server for Health Sciences|September 15, 2025
Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohortsAdrian Gervais, Francesca Trespidi, Alessandro Ferrari, et al.
Journal of Human Immunity|March 16, 2026
Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohortsAdrian Gervais, Francesca Trespidi, Alessandro Ferrari, et al.
The Journal of Allergy and Clinical Immunology|November 7, 2023
JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective studyMarco Fischer, Peter Olbrich, Jérôme Hadjadj, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2026
ASSESSMENT OF TREC-BASED NBS SCID REPORTING PRACTICES FOR HARMONIZATION OF RESULTS AND INTERPRETATION: A GLOBAL SURVEYJahnavi Aluri, Amy Gaviglio, Isaac Kistler, et al.
Research Square|January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodiesJeremy Manry, Paul Bastard, Adrian Gervais, et al.
Pageof 10